Mucin Production by Human Colonic Carcinoma Cells Correlates with Their Metastatic Potential in Animal Models of Colon Cancer Metastasis

Robert S. Bresalier,* Yaron Niv,* James C. Byrd,* Quan-Yang Duh,† Neil W. Toribara,* Richard W. Rockwell,* Rajvir Dahiya,* and Young S. Kim†
Veterans Administration Medical Center and Departments of*Medicine and †Surgery, University of California, San Francisco, San Francisco, California 94121

Abstract

Patients with mucinous colorectal cancers characteristically present with advanced disease, however, the relationship between mucin production by colon cancer cells and their metastatic potential remains unclear. We therefore sought to define the relationship between mucin production by human colon cancer cells and metastatic ability by employing animal models of colon cancer metastasis. LS LiM 6, a colon carcinoma cell line with high liver metastasizing ability during cecal growth in nude mice produced twofold more metabolically labeled intracellular mucin and secreted four- to fivefold more mucin into the culture medium compared to poorly metastatic parental line LS174T. This was accompanied by a similar elevation in poly(A)* RNA detected by blot hybridization with a human intestinal mucin cDNA probe, and increases in mucin core carbohydrate antigens determined immunohistochemically.

Variants of LS174T selected for high (HM 7) or low (LM 12) mucin synthesizing capacity also yielded metastases after cecal growth and colonized the liver after splenic-portal injection in proportion to their ability to produce mucin. Inhibition of mucin glycosylation by the arylglycoside benzyl-α-N-acetylglucosamine greatly reduced liver colonization after splenic-portal injection of the tumor cells. These data suggest that mucin production by human colon cancer cells correlates with their metastatic potential and affects their ability to colonize the liver in experimental model systems. (J. Clin. Invest. 1991. 87:1037–1045.) Key words: carbohydrates • glycosylation • adenocarcinoma • cecum • liver

Introduction

Patients with mucinous adenocarcinomas of the colon often present with advanced disease, and have been reported to have a poor prognosis (1–6). Whereas many authors report a lower survival for patients with mucinous cancers compared to those with "nonmucinous" tumors, others have failed to find a significant correlation between this histologic pattern and prognosis (6). This controversy may relate in part to the lack of adequate quantitation of mucin production in most histochemical studies, and to variable definitions of "mucinous carcinoma" in the literature. Some studies suggest, for example, that only tumors which produce large amounts of mucin may be associated with a poor prognosis (4).

The relationship between mucin production by colon cancer cells and their metastatic potential is even less clear. The incidence of local invasion and recurrence appears high for mucinous colorectal cancers (4, 6), but the incidence of distant metastasis is poorly documented.

A detailed understanding of the biological behavior of human colon cancer cells and metastasis may be furthered by appropriate in vivo models which accurately reflect the events in this complex process. We have recently described an animal model for colon cancer metastasis (7, 8) which was used to establish and characterize human colon cancer cells which differ in their liver-metastasizing ability during cecal growth. Colon cancer cells which produce high or low amounts of mucin relative to the same parental cell line have also been previously selected in our laboratory (9). In the current series of experiments we were therefore able to quantitate mucin production by human colon cancer cells of known metastatic ability, and conversely to assess the metastatic potential of colon cancer cells which differ in their capacity to produce mucin. The effect of mucin glycosylation on experimental liver colonization was also studied using a compound which competitively inhibits mucin glycosylation with little effect on cell growth or viability (10).

Methods

Cell lines. Parental colon cancer cell line LS174T was derived from a well-differentiated human colon adenocarcinoma (11), and has been characterized extensively, including its ability to produce mucin in vitro (9), and when grown subcutaneously in athymic nude mice (12). Cells injected into the cecal wall of nude mice produce well-differentiated primary colon cancers with little metastatic ability (7).

LS LiM 6, a derivative of LS174T with high liver-metastasizing ability during cecal growth, was established by serially selecting cells which metastasized from cecum to liver as previously described (7). These cells form well-differentiated mucinous carcinomas in nude mice, with large glands containing PAS-positive mucin comprising ~ 50% of the tumor area. HM7 and LM12 are variants of LS174T which produce high and low amounts of mucin, respectively, relative to the parental cell line, and were selected by a replica plating and immunoscreening method as previously described (9). HM7 secretes approximately twofold more mucin in culture and contains twofold

1. Abbreviations used in this paper: benzyl-α-GalNAc, benzyl-α-N-acetylglucosamine; CMF, calcium and magnesium-free phosphate buffered saline; GlcNAc, N-acetylgalactosamine; PAS, periodic-acid-Schiff.
more intracellular mucin compared with LS174T, whereas LM12 produces ~ 30% less mucin overall compared with the parental line (9). HM7 forms well differentiated tumours in nude mice, with prominent glands containing PAS-positive mucin comprising 40–50% of the tumour area. In contrast, LM12 xenografts contain fewer mucin-containing glands comprising < 10% of the tumor area (8).

All cell lines were grown and maintained in DMEM supplemented with 10% fetal bovine serum, penicillin (100 U/ml), and streptomycin (100 μg/ml), in a 5% CO2 environment. Early passage cell lines (passaged fewer than 15 times) were used for all studies.

**Metabolic labeling of cells.** Cells were grown to confluency in 25-cm2 tissue culture flasks as above, then labeled for 24 h in low-glucose DMEM H-16 medium (Gibco, Grand Island, NY) containing 1 μCi/ml [3H]glucosamine (sp act 30 Ci/mmol) (9). Numbers were determined from parallel flasks. After 24 h, the cells were chilled on ice and the medium removed. The cell layer was scraped in PBS pH 7.4 and added to the medium for centrifugation (600 g for 10 min). The medium supernatant was collected, and the cell pellet sonicated on ice in 10 mM Tris buffer pH 8.0. Cell homogenates were ultracentrifuged at 100,000 g for 1 h, and the supernatant designated as the cytosol component.

**Gel filtration of labeled glycoproteins.** The medium and cytosol fractions were subjected to gel filtration on sepharose CL-4B columns (1 x 43.5 cm) (9, 10, 12). Samples of 1 ml were applied, and the columns eluted at 4°C with 10 mM Tris-HCl buffer, pH 8.0. Fractions of 0.8 ml were collected and radioactivity determined by liquid scintillation counting. The results were corrected for counting efficiency and cell number, and expressed as counts per minute per 4 x 106 cells as previously described (9).

**Chemical and enzymatic degradation.** Void volume material was analyzed subsequently to reduce clevage of O-glycosidic linkages (β-elimination), or digestion with trypsin, hyaluronidase, heparitinase, or chondroitinase ABC as previously described (9).

**CsCl centrifugation.** CsCl (0.54 g/ml) was added to the void volume material and the solution centrifuged for 72 h at 160,000 g in a model SW-41 rotor (Beckman Instruments, Inc., Fullerton, CA) at 5°C. Fractions of 1.0 ml were removed and weighed to determine density and counted.

**Mucin RNA blot analysis.** RNA purification and poly(A)+ RNA isolation, gel electrophoresis, transfer to nylon membranes, and hybridization probe analysis were performed as previously described (13). Poly(A)+ RNA blots were probed with cDNA SMUC 41, which encodes a threonine- and proline-rich consensus sequence of human intestinal mucin (14). Control lanes were examined with a probe encoding a 960-bp fragment of the human glyceraldehyde-3-phosphate dehydrogenase gene (15).

**Glycosyltransferase assays.** Cultured cells (75% confluent monolayer cultures) were washed three times with PBS and harvested by scraping into 8 ml PBS with a cell scraper. Cells were centrifuged, and the cell pellet was suspended and sonicated in 1 ml PBS (pH 7.1). Aliquots were used directly for glycosyltransferase assays or frozen at –70°C.

β1-4 Galactosyltransferase activity was determined as previously described (16) using a reaction mixture consisting of 0.1 M cacydate buffer (pH 6.8), 20 mM MgCl2, 200 μM ATP, 10 mM GlicNac, 17–20 μM UDP-[3H]galactose (50,000–60,000 cpm), 50–100 μM cellular protein, and 0.1% triton X-100 in a total volume of 100 μl (17).

Polyepitidyl N-acetylgalactosaminyl transferase activity was determined using myelin basic protein (100–200 μg) as acceptor and 5.4 μM UDP-[14C]N-acetylgalactosamine (40,000 cpm) as donor. Assays for β1-3 galactosyltransferase activity utilized asialo-ovine submaxillary mucin (100–200 μg) as acceptor and 0.12 μM UDP-[3H]galactose (14,000 cpm) as nucleotide-sugar donor. Assay mixtures contained 0.1 M cacodylate buffer (pH 6.8), 20 mM MgCl2, 0.1% triton X-100, 200 μM ATP, and 25–100 μg enzyme in a total volume of 100 μl (17). Reaction mixtures were incubated at 37°C for 90 min, and the reaction terminated by the addition of 2 ml ice-cold 1% phosphotungstic acid in 0.5 M HCl. Precipitates were washed three times with cold phospho-

tungstic acid and dissolved in 600 μl Omnios tissue solubilizer (ICN Biomedicals, Inc., Irvine, CA), and counted with 10 ml Omnifluor (New England Nuclear, Boston, MA) tolune scintillation cocktail. Net radioactivity transferred to exogenously added acceptor was determined after subtracting the amount of radioactivity transferred to endogenous acceptors.

All assays were performed within the linear range of both enzyme concentration and incubation time. The amount of donor (unlabeled and labeled) used in each case yielded optimum transfer of labeled donor to acceptor.

**Cecal injection.** Confluent cultures were harvested by brief trypsinization (0.05% trypsin–0.02% EDTA in HBSS without calcium and magnesium), washed several times with calcium and magnesium-free phosphate-buffered saline (CMF), and resuspended at a final concentration of 5 x 106 cells/ml in serum-free medium. The presence of single-cell suspensions was confirmed by phase-contrast microscopy, and cell viability was determined by Trypan blue exclusion. Pathogen-free BALB/c NCR-NU athymic mice (3- to 5-wk-old females obtained from the National Cancer Institute, Frederick, MD) were anesthetized, the cecum exteriorized, and 5 x 106 viable tumor cells in 0.1 ml injected into the cecal wall as previously described (7, 8). The cecum was replaced in situ, and the abdomen closed with stainless steel clips. After 6 wk animals were sacrificed by cervical dislocation and the abdominal organs and thorax examined for the presence of macroscopic “primary” cecal tumors and metastases. Macroscopic metastases were defined as those visible to the naked eye. Organs including cecum, liver, mesenteric nodes, and lungs were removed and fixed in 10% formalin for 24 h. Representative tissues were embedded in paraffin and serial 5-μm sections cut, stained with hematoxylin-eosin and periodic-acid-Schiff (PAS), and examined by light microscopy to verify the presence of metastases.

**Splenic injection (liver colonization assay).** The ability of the various tumor cells to colonize the liver after entry into the hepatic-portal system was tested in a modification of a splenic injection model (18, 19), as previously described (16). Tumor cells were grown to confluency in 75-cm2 tissue culture flasks, harvested as described for cecal injection, and resuspended in serum-free DMEM at a concentration of 106 cells/ml. Athymic nude mice were anesthetized with methoxyflurane by inhalation, prepared steriley, and the spleen exteriorized through a flank incision. One million cells in 100 μl were slowly injected into the splenic pulp through a 27-gauge needle over 1 min, followed by splenectomy 1 min later. Animals were sacrificed 3–4 wk later, the livers removed and weighed, and tumor nodules were counted.

The immediate fate of tumor cells after splenic injection was determined by injection of IdURO-labeled tumor cells. Cells were grown as above and 0.5 μCi/ml [3H]IdURO was added to culture medium 24 h before harvesting (16). This concentration of isotope labels > 95% of tumor cells without affecting viability. Cells were prepared and injected into the splenic pulp as described above. Animals were sacrificed 10 min after injection, and the livers removed. The radioactivity present in the spleen (removed after injection), liver, and remaining organs of each animal was determined by gamma-counting in a model 7000 counter (Beckman Instruments Inc.).

**Liver colonization after inhibition of mucin glycosylation.** Tumor cells were grown to 50% confluency in 75-cm2 tissue culture flasks as described above. The tissue culture medium was then aspirated, and replaced with fresh medium containing 2 mM benzyl-α-N-acetylgalactosamine (benzyl-α-GalNAc) (10). Cells were harvested 48 h later, and liver colonization assayed after splenic injection as above.

In a separate experiment, tumor cells were grown for 48 h in medium containing 2 mM benzyl-α-GalNAc as above. The cells were then washed three times with CMF, and the medium replaced with DMEM containing 10% FBS. After an additional 48 h, the cells were harvested and liver colonization assayed after splenic-portal injection. Parallel flasks were grown for 96 h in DMEM plus FBS or DMEM containing 2 mM benzyl-α-GalNAc (n = 6 animals per group).

**Tumorigenicity of benzyl-α-GalNAc–treated cells.** The tumorigenic-

1038 Bresalier, Niv, Byrd, Duh, Toribara, Rockwell, Dahiya, and Kim
ity of benzyl-α-N-acetylgalactosamine-treated cells was verified and compared with untreated cells after subcutaneous injection into athymic nude mice. Cells were grown to confluency in the presence or absence of 2 mM benzyl-α-GalNAc as above, harvested, and resuspended to a concentration of 5 × 10⁶ cells/ml in serum-free DMEM. 5 × 10⁴ viable tumor cells in 0.1 ml were inoculated subcutaneously into the left posterior flank of 3–5-wk-old athymic mice which were observed daily for tumor growth. Tumors were measured with a caliper at least every other day, and tumor volume calculated as previously described (9).

**Immunocytochemistry.** Cells were grown as above, and seeded into eight-well chamber slides (Lab-Tek, Becton, UT) at a density of 3 × 10⁵ cells per well, and grown to confluency in DMEM supplemented with 10% FCS at 37°C in a 7% CO₂ atmosphere. Cells were then washed twice with PBS, fixed with 100% ethanol/5% acetic acid (20), washed, and used for immunocytochemical studies using the streptavidin-peroxidase technique (21). For monoclonal antibodies, negative controls consisted of substituting normal mouse IgM for primary antibody and PBS for primary and secondary antibodies. In all cases, when primary antibody was omitted, a negative staining pattern was obtained. Controls for lectins substituted PBS for lectins in the reaction. Additionally, specificity was confirmed by incubating equal volumes of lectin and 0.5 M hapten sugar before incubation with cells in duplicate chamber slides. Staining intensity was graded as weak (+), moderate (++), or strong (+++) (20).

**Statistical analysis.** Statistical analyses were performed as determined to be appropriate by an independent analyst. These included the Fisher exact test (number of metastasis-bearing mice after cecal injection), unpaired Student’s t test (liver weight, percent of input counts detected in the liver, specific activity of glycosyltransferases), and the Mann-Whitney test (number of tumor nodules after splenic-portal injection). For the purposes of the latter analysis, if a liver contained > 500 nodules (too numerous to count), an arbitrary value of 500 nodules was used.

**Results**

**Mucin production by human colon cancer cells of known metastatic potential.** Human colon cancer cell line LS174T, derived from a well-differentiated cancer, produced hepatic parenchymal metastases after cecal growth in 2 of 30 nude mice. This low metastatic rate is similar to that previously described for this cell line (7). Liver metastases from LS174T were grown in culture, expanded, reinserted into the cecum of additional animals, and the process repeated six times (7) to select LS LiM 6 which produced hepatic metastases in 11 of 15 animals bearing cecal tumors (P < 0.001 LiM 6 vs. LS174T).

In addition, LS LiM 6 colonized the liver to a greater extent than LS174T after introduction into the portal system. 4 wk after intrasplenic injection of LS LiM 6, the livers of all animals (n = 12) were substantially replaced by tumor (mean liver weight±SD 4.75±1.85 g; tumor nodules too numerous to count), whereas LS174T (n = 12 animals) produced relatively little hepatic tumor burden (mean liver weight, 1.28±0.35 g; range, 2–30 nodules; P < 0.001 for difference in number of nodules). This difference in liver colonization was not the result of differences in the number of tumor cells initially reaching the liver, because this was similar 10 min after intrasplenic injection of [125I]dUR-labeled cells (72.5±10.8% of input counts, LS174T; 74.9±7.1%, LS LiM 6; n = 6 animals per group; NS).

The production of high–molecular weight mucin-type glycoproteins by LS174T and LS LiM 6 was quantitated by size exclusion chromatography on Sepharose CL-4B. Cells were metabolically labeled with [3H]glucosamine, medium and cytosol fractions subjected to gel filtration, and the high–molecular weight radioactivity in the void volume initially taken as representative of mucin (9). Fig. 1 shows the gel filtration profiles of newly synthesized labeled glycoproteins secreted into the medium and from the cytosol fractions of parental cell line LS174T and liver-metastasizing cell line LS LiM 6. Three separate experiments demonstrated a four- to fivelfold increase in high–molecular weight labeled material secreted into the medium by metastatic LiM 6 compared to LS174T, and a twofold increase in intracelular high–molecular weight radiolabel in the metastatic cell line. The high–molecular weight labeled material from the void volume was highly susceptible to alkaline borohydride reductive cleavage, but resistant to degradation by trypsin, chondroitinase ABC, hyaluronidase, heparitinase, and N-glycanase, further indicating that this material is mucin (9). This was also supported by cesium chloride density centrifugation (9, 22).

Mucin poly(A)* messenger RNA determined by blot hybridization with human intestinal mucin cDNA SMUC 41 (14) was found to be proportionally increased in LS LiM 6 compared to LS174T (Fig. 2), whereas control lanes probed with a cDNA encoding the glyceraldehyde-3-phosphate dehydrogenase gene showed equal signals.

The expression of the colon cancer-mucin-associated core carbohydrate structures T (Galβ3GalNAc), Tn (GalNacαThr), and sialyl Tn (Siaα6GalNAcα) (23) was also elevated in LS LiM 6 compared to LS174T as determined by immunohistochemical analysis of cultured cells. Staining intensity for mucin structures was weak in LS174T and strong in LS LiM 6 (Fig. 3). This was accompanied by a 1.6-fold increase in β1,3 galactosyltransferase (the enzyme responsible for synthesizing the mucin core structure Galβ3GalNAc) in LS LiM 6 (11.56±1.22 pmol/mg protein per h, LS LiM 6 vs. 7.12±0.91, LS174T; n = 5 experiments with triplicate determinations; P < 0.001), whereas there was no significant difference in polypeptidyl N-acetylgalactosaminyl transferase or β1,4 galactosyltransferase activity between the cell lines.

**Metastatic ability of human colon cancer cells which differ in their capacity to produce mucin.** Cell lines LM 12 and HM 7 are variants of LS174T which produce low and high amounts of mucin, respectively, compared to the parental cell line, and have been well characterized as to their mucin production in vitro (9) and when grown as xenografts in nude mice (12). The spontaneous metastatic potential of these cell lines during cecal growth was compared to LS174T as previously described (7), as was their ability to colonize the liver after introduction into the hepatic portal system (16). Ceca injection of LM 12 or LS174T produced few metastases, whereas HM 7 produced regional lymph node or hepatic metastases in the majority of animals tested (Table I). In addition, these cell lines colonized the liver after splenic-portal injection in proportion to their ability to produce mucin (Table II, Fig. 4). Little hepatic tumor burden was evident 3 wk after introduction of LM 12 or LS174T into the portal system, whereas extensive liver colonization was seen after injection of high mucin-producing HM 7. These differences in liver colonization were not due to differences in the number of tumor cells reaching the liver after splenic injection as demonstrated by injection of [125I]dUR-labeled tumor cells. There were no significant differences in the number of tumor cells detected in the liver 10 min after splenic injection of the various cell lines (66.6±2.2% of input counts, LM 12; 71.7±5.6% LS174T; 67.3±8.94%, HM 7; n = 8 animals per group).
Liver colonization after inhibition of mucin glycosylation. The functional relationship between mucin production by colon cancer cells and their ability to colonize the liver was further studied by examining the effect of inhibition of mucin glycosylation on experimental liver colonization. Benzyl-α-N-acetylgalactosamine (benzyl-α-GalNAc) is an analogue of N-acetylgalactosamine, the first sugar in the mucin core region. This compound can compete as an acceptor for the elongation of oligosaccharides by glycosyltransferases and inhibit the formation of fully glycosylated mucin in a dose-dependent manner without affecting cell growth or viability (10). Growth of LS LiM 6 and HM 7 for 48 h in medium containing 2 mM benzyl-α-GalNAc inhibited the production of high-molecular weight glycosylated mucin in these cell lines by 89% and 77%, respectively (Fig. 5). A similar inhibition (82%) has been previously demonstrated for parental cell line LS174T (10). Growth of mucin-producing cell lines HM 7 and LiM 6 in the presence of benzyl-α-GalNAc before splenic-portal injection greatly reduced subsequent liver colonization compared to untreated controls (Fig. 6; Table III). Growth of cells in benzyl-α-GalNAc before injection did not alter the number of viable tumor cells leaving the spleen and initially reaching the liver as determined by injection of [125I]dU-labeled tumor cells. Tumorogenicity in athymic nude mice was similar after subcutaneous injection of cells grown in the presence or absence of benzyl-α-GalNAc, and subcutaneous tumor volume doubling times were also similar (data not shown). In a separate experiment cell line HM7 was allowed to recover from benzyl-α-GalNAc-induced mucin inhibition in culture before assessment of liver colonization. Liver colonization after a 48-h wash out of benzyl-α-GalNAc was similar in degree to previously untreated controls (Table III), again suggesting a role for mucin in this process.

Discussion

Alterations in cell surface and secreted glycoproteins are associated with carcinogenesis, and may play a significant role in
determining the metastatic behavior of tumor cells (24, 25). Mucins are the major secreted glycoproteins of the colon, and quantitative changes in these high-molecular weight O-linked glycoproteins could alter the biological behavior of tumors arising from this epithelium (9). Mucins extracted from colon cancers may be distinct from those of the normal colon (26–30), and alterations in colonic mucin have been reported in preneoplastic conditions such as familial polyposis (31) and ulcerative colitis (32). Histochemical and immunohistochemical studies have demonstrated differences in lectin reactivity and carbohydrate antigen expression between mucins of normal colon, colon cancer, and preneoplastic colonic adenomas (23, 26, 33–35). Colon cancer cells of high metastatic potential may produce mucins which lack certain exposed oligosaccharide receptors (30, 36), and may differ in their expression of sialylated mucin-associated structures (37, 38). Patients with mucinous adenocarcinomas of the colon often present with advanced disease and have a poor prognosis (1–6). The relationship between the amount of mucin produced by these tumors and their biological behavior, however, remains unclear (9). Because colon cancer–related mortality is most closely associated with the extent of metastasis at diagnosis, we have studied the relationship between mucin production by human colon carcinoma cells and metastasis using animal models of colon cancer metastasis which simulate human disease (7, 8, 16).

LS LiM 6, a cell line derived from parental human colon cancer line LS174T, was selected for its ability to metastasize to the liver parenchyma during orthotopic growth in the cecum of nude mice. These cells are therefore capable of participation in all stages of the metastasis cascade (25, 39) which simulate human disease (7, 8). Their ability to participate in the terminal stages of metastasis was confirmed by the high rate of liver colonization after introduction into the portal system compared to LS174T.

LS LiM 6 produced twofold more metabolically labeled

Table I. Metastatic Abilities of Human Colon Cancer Cells

<table>
<thead>
<tr>
<th>Cell line</th>
<th>Number of metastasis-bearing mice*</th>
<th>Liver</th>
<th>Regional lymph nodes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Parenchyma</td>
<td>Hilus</td>
<td>Total</td>
</tr>
<tr>
<td>LM 12</td>
<td>0/12</td>
<td>0/12</td>
<td>0/12</td>
</tr>
<tr>
<td>LS174T</td>
<td>1/12</td>
<td>0/12</td>
<td>1/12</td>
</tr>
<tr>
<td>HM 7</td>
<td>4/12</td>
<td>5/12</td>
<td>9/12</td>
</tr>
</tbody>
</table>

Metastatic potential of cancer cells after injection and formation of experimental cecal primary tumors. Animals were sacrificed 6 wk after injection of 5 × 10^6 cells into the cecal wall. * Parenchymal metastases are those present within the substance of the liver. Hilar metastases represent cases where tumor was present within the portal vein and lymphatics of the liver hilus. † P < 0.02 vs. LS174T or LM 12. ‡ P < 0.002 vs. LS174T or LM 12. § P < 0.001 vs. LS174T or LM 12.

Table II. Liver Colonization after Intraspinal Injection of Human Colon Cancer Cells

<table>
<thead>
<tr>
<th>Cell line</th>
<th>Liver weight†</th>
<th>Number of tumor nodules (range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>LM 12</td>
<td>1.22±0.07</td>
<td>0–2</td>
</tr>
<tr>
<td>LS174T</td>
<td>1.24±0.38</td>
<td>2–30†</td>
</tr>
<tr>
<td>HM 7</td>
<td>2.36±0.07†</td>
<td>&gt;500‡</td>
</tr>
</tbody>
</table>

Hepatic tumor burden 3 wks after intrasplenic injection of 10^6 tumor cells (n = 10 animals per group). * Mean±SD. † P < 0.05 vs. LM 12. ‡ P < 0.001 vs. LS174T.
intracellular mucin and secreted four- to fivefold more mucin into the culture medium compared with poorly metastatic LS174T, as determined by size exclusion chromatography. The mucinous nature of this material has been previously established for LS174T and several of its derivatives (9, 10) and was confirmed for the metastatic variant. Poly(A)' messenger RNA encoding the mucin apoprotein was similarly elevated in LS LiM 6 compared to the parental line, as were three partially glycosylated mucin-associated core structures. Thus, multiple lines of evidence confirm increased mucin synthesis by the highly metastatic cell line.

In a second set of experiments, variants of LS174T selected for high (HM 7) or low (LM 12) mucin-synthesizing capacity were compared for their ability to metastasize and colonize the liver of nude mice. These cell lines have been previously shown to produce quantitatively high or low amounts of metabolically

Figure 5. Sepharose CL-4B profiles of [3H]glucosamine-labeled glycoproteins secreted into the medium or from the cytosol fractions of human colon cancer cell line LS LiM 6 grown for 48 h in the presence or absence of 2 mM benzyl-α-N-acetylgalactosamine (BzGalNAc). A similar inhibition of mucin production by benzyl-α-GalNAc has been demonstrated for cell lines LS174T and HM 7 (data not shown).
labeled mucin compared with the parental cell line. Few metastases to the liver or regional lymph nodes were evident during cecal growth of LM 12 or LS174T, whereas HM 7 produced metastases to the liver hilus or parenchyma in 75% of experimental animals, and regional lymph node metastases in 90%. Liver colonization after splenic-portal injection of the various cell lines was also proportional to their ability to produce mucin, suggesting a possible role for mucin in the terminal stages of metastasis. While Jessup et al. (40) did not find a correlation between mucin production and tumorigenicity or metastasis of human colon cancer cells in nude mice, their assessment was based on histological evaluation of hematoxylin-eosin stained tissue sections, and not a biochemical quantitation of mucin production.

A functional relationship between mucin-type glycoproteins and the ability of colon cancer cells to metastasize was further suggested by experiments employing benzyl-α-N-acetylgalactosamine, a competitive inhibitor of mucin glycosylation. Growth of LS LiM 6 and HM 7 in the presence of benzyl-α-GalNAc inhibited the production of fully glycosylated mucin by 80–90% in these cells. Liver colonization after splenic-portal injection was significantly reduced for both cell lines after inhibition of mucin glycosylation. This was not the result of alterations in cell viability or tumorigenicity as demonstrated in vitro by exclusion of vital dyes and growth curves (10), and in vivo by subcutaneous growth of these cells. The number of tumor cells leaving the spleen and initially reaching to liver after splenic-portal injection was not affected by growth with benzyl-α-GalNAc, as determined by tracking of 125I-dUTP-labeled tumor cells. This again suggests a possible role for mucin-type glycoproteins in the terminal stages of liver colonization in this model.

Tumor cell–associated glycoproteins may play a significant role in various stages of metastasis (16, 24, 25, 28, 30, 36–38, 41–43) including invasion, tumor cell–mediated platelet aggregation, resistance to immune destruction, and tumor cell adhesion to basement membrane components and target cells. Carcinoembryonic antigen, a heavily N-glycosylated member of the immunoglobulin superfamly (44), is an integral cell surface component of colon carcinoma cells which is shed into the serum and may, for example, participate in the adhesion of tumor cells in the liver (40). Alterations of the glycosylation of cell surface glycoproteins may interfere with tumor cell adhesion in target organs because certain molecules may act as endogenous lectins (43). Tunicamycin, a compound which inhibits the synthesis of N-linked glycoproteins, decreases tumor cell–endothelial binding and the ability of melanoma cells to colonize the lungs of experimental animals (45). Tunicamycin also affects the expression of the ASGP-1 sialoglycoprotein on mammary tumor ascites cells, and increases susceptibility to natural killer cell–mediated tumor cell lysis (46). Swainsonine, another inhibitor of the glycosylation of N-linked glycoproteins may

Table III. Effect of Inhibition of Mucin Glycosylation on Liver Colonization by Human Colon Cancer Cells

<table>
<thead>
<tr>
<th>Cell line</th>
<th>Liver weight*</th>
<th>Number of tumor nodules (range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HM 7</td>
<td>2.45±0.80</td>
<td>70-&gt;500</td>
</tr>
<tr>
<td>HM 7 + benzylαGalNAc</td>
<td>1.24±0.24</td>
<td>2-14†</td>
</tr>
<tr>
<td>LiM 6</td>
<td>4.78 ± 2.15</td>
<td>40-&gt;500</td>
</tr>
<tr>
<td>LiM 6 + benzylαGalNAc</td>
<td>1.19±0.28</td>
<td>1-11†</td>
</tr>
</tbody>
</table>

* Mean±SD. † P < 0.01 vs. untreated cells. § P < 0.001 vs. untreated cells. 

Hepatic tumor burden 3 wk after intrasplancic injection of 106 tumor cells (n = 9 animals per group). Cells were grown for 48 h in the presence of absence of 2 mM benzyl-α-N-acetylgalactosamine.

Figure 6. Livers from athymic nude mice 3 wk after intrasplancic injection of human colon cancer cell line HM 7 grown in the presence (+) or absence (−) of benzyl-α-N-acetylgalactosamine.

Mucin Production by Human Colonic Carcinoma Cells 1043
also affect the late stages of liver colonization by melanoma cells (47). It is possible that benzyl-α-GalNAc similarly inhibits the formation of O-linked mucin type glycoproteins necessary for heterotypic cell–cell or cell–substratum interactions in the liver. In this regard, Trimmer et al. (38, 48) have characterized high-molecular weight mucin-type sialoglycoproteins which are differentially expressed on metastatic human colon carcinoma cells grown in culture and in tumor tissues. Mucin produced by LS174T and its derivatives is highly sialylated (12), and we have previously shown that sialic acid may play a role in the ability of murine colon cancer cells to colonize the liver (16). Immunohistochemical analysis of metastatic derivatives of LS174T in vitro (this study), and comparison of primary cecal tumors and liver metastases derived from LS174T in nude mice (37) also demonstrate quantitative differences in the expression of sialylated mucin-associated carbohydrate structures similar to those found in human tissues. Sialoglycoproteins may play a role in many stages of metastasis including adhesive interactions and resistance to immune surveillance (16, 25, 38, 46, 48). This study provides further evidence that mucins are associated with colorectal cancer metastasis and liver colonization. The functional relationship of specific mucin-associated structures to the various stages of metastasis is currently under investigation.

Acknowledgments

The authors wish to thank Rita Burns for preparation of the manuscript.

Supported by the Research Service of the Veterans Administration through VA Research Associate (RSB), Merit Review (RSB, YSK), and Medical Investigator (YSK) awards, and National Cancer Institute Grant CA45967 (YSK).

References


